Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rasi On Brexit: ‘EMA Is Well-Oiled Machine That We Cannot Afford To Start Stuttering’

Executive Summary

European Medicines Agency head Guido Rasi tackles issue of Brexit in agency’s 2016 annual report, saying EMA is “core building block of the common market for medicines in the EU” that operates like “well-oiled machinery.”

You may also be interested in...



Race Hots Up For EMA After Brexit

France has officially named Lille as the city it would like to host the European Medicines Agency once the UK leaves the EU, and Italy has appointed an ambassador to promote Milan’s bid for the agency. Meanwhile, stakeholders in Denmark are joining forces to stress why Copenhagen would be a good choice, and Ireland, the Netherlands and Austria have all confirmed their candidacies.

Brexit: Scenario Planning Well Under Way At EMA

The EMA has outlined some of the planning that has been going on in preparation for its relocation from the UK to another EU member state as a result of Brexit, including ongoing relations with the UK regulator, the MHRA.

Brexit: EMA Could Lose Up To Half Its Staff If It Has To Move

The European Medicines Agency is working to ensure it can cope with the many challenges it will face as a result of the UK leaving the EU. Those challenges could include the agency losing 50% of its staff, according to the EMA’s deputy head Noel Wathion.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel